Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Neuropharmacology. 2014 Jul 15;86:161–173. doi: 10.1016/j.neuropharm.2014.07.006

Table 2. Summary of statistical analysis of long-term adolescent (P35–P55) cannabinoid effects on normalized oscillation power in adult mPFC.

Cannabinoid effects were compared between treatment conditions with KS tests. Percentages reported are the median normalized LFP power in the treatment after “vs” relative to the median normalized LFP power in the treatment before “vs” in the statistical comparison.

Long-Term Adolescent Cannabinoid Treatment mPFC
Adolescent THC Treatment
Vehicle (n = 60 slices/26 mice) vs. THC (5 mg/kg) (n = 21 slices/7 mice)
p< 0.001, 51%
Adolescent AM251 Treatment
Vehicle (n = 60 slices/26 mice) vs. AM251 (0.3 mg/kg) (n = 12 slices/4 mice)
Vehicle (n = 60 slices/26 mice) vs. AM251 (0.5 mg/kg) (n = 11 slices/4 mice)
Vehicle (n = 60 slices/26 mice) vs. AM251 (1.0 mg/kg) (n = 7 slices/3 mice)
p < 0.001, 43%
p< 0.001, 58%
p = 0.010, 63%
Adolescent WIN Treatment
Vehicle (n = 60 slices/26 mice) vs. WIN (1 mg/kg) (n = 50 slices/20 mice)
p< 0.001, 56%
Adolescent AM 4113 Treatment
Vehicle (n = 60 slices/26 mice) vs. AM4113 (1 mg/kg) (n = 19 slices/8 mice)
p = 0.031, 78%
Adolescent AM630 Treatment
Vehicle (n = 60 slices/26 mice) vs. AM630 (1 mg/kg) (n = 15 slices/6 mice)
p < 0.001, 53%
Adolescent WIN-3 Treatment
Vehicle (n = 60 slices/26 mice) vs. WIN-3 (1 mg/kg) (n = 18 slices/7 mice)
p< 0.001, 49%